ABT-869 | 1615

ABT-869 is multi-targeted inhibitor of all members of the VEGF and PDGF receptor families (e.g., KDR, IC₅₀ value of 4 nM), but has much less activity (IC₅₀ values >1 µM) against unrelated receptor tyrosine kinases, soluble tyrosine kinases or serine/threonine kinases. The kinase inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC₅₀ values of 2, 4 and 7 nM for PDGFRβ, KDR and CSF-1R, respectively) and VEGF-stimulated proliferation (0.2 nM IC₅₀ for human endothelial cells).

ABT-869 is multi-targeted inhibitor of all members of the VEGF and PDGF receptor families (e.g., KDR, IC₅₀ value of 4 nM), but has much less activity (IC₅₀ values >1 µM) against unrelated receptor tyrosine kinases, soluble tyrosine kinases or serine/threonine kinases.

1615 | ABT-869 DataSheet

Alternate Name/Synonyms: Linifanib

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 796967-16-3

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₁H₁₈FN₅O

Molecular Weight: 375.41

Cell-Permeable?: Yes

Purity: ≥99%

Solubilities: DMSO

Handling: Protect from air and moisture

Country of Origin: USA

Tag Line: A VEGFR and PDGFR kinase inhibitor

MDL Number: MFCD11840918

PubChem CID: 11485656

SMILES: CC1=CC(=C(C=C1)F)NC(=O)NC2=CC=C(C=C2)C3=C4C(=CC=C3)NN=C4N

InChi: InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25, 28)

InChi Key: MPVGZUGXCQEXTM-UHFFFAOYSA-N